The development of bispecific antibodies to promote proapoptotic immunotherapy in pancreatic cancer

在过去的40年里，英国的胰腺癌存活率没有任何改善。目前只有不到5%的人在确诊后能存活5年。这是一种高度复杂的疾病，对目前大多数治疗策略（如化疗和放疗）具有耐药性。因此，迫切需要尝试开发更有效的方法来治疗这一毁灭性疾病。这个项目;通过与在医学研究行业拥有超过15年经验的Fusion Antibodies Ltd合作，将开发和评估一种针对胰腺癌的新型双特异性抗体。使用双特异性抗体的主要优点是其结合两个不同靶标的独特能力。这种抗体将被设计成既能与肿瘤细胞相互作用，又能与周围微环境中的细胞相互作用。其目的是诱导肿瘤细胞死亡，同时也引起免疫系统关键激活成分的刺激和成熟。最终，希望这个项目将导致胰腺癌治疗的新治疗策略的发展，这是一个迫切的临床需求领域。

Over the last 40 years in the U.K. there has been no improvement in pancreatic cancer survival rates. Currently less than 5% survive 5 years after diagnosis with the disease. It is a highly complex disease that is resistant to most current treatment strategies such as chemotherapy and radiotherapy. As such there is an urgent need to try develop more effective ways of treating this devastating disease. This project; through collaboration with Fusion Antibodies Ltd, who have over 15 years' experience in the medical research industry, will develop and evaluate a novel bispecific antibody designed to target pancreatic cancer. The main advantage of using a bispecific antibody is its unique ability to bind to two distinct targets. The antibody will be designed so that it interacts with both tumour cells, and cells in the surrounding microenvironment. The aim is to induce tumour cell death while also causing the stimulation and maturation of key activating components of the immune system. Ultimately it is hoped this project will lead to the development of a new therapeutic strategy for the treatment of pancreatic cancer, an area of acute clinical need.